Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rifaquizinone - TenNor Therapeutics

Next Previous
Search
Drug Profile

Rifaquizinone - TenNor Therapeutics

Alternative Names: CBR-2092; TNP-2092; TNP-2092 Capsule; TNP-2092 IV; TNP-2092 PO

Latest Information Update: 18 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cumbre Pharmaceuticals
  • Developer TenNor Therapeutics
  • Class Antibacterials; Cyclopropanes; Fluorinated hydrocarbons; Irritable bowel syndrome therapies; Piperidines; Quinolizines; Rifamycins
  • Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase inhibitors; DNA-directed RNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Bacterial infections
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Bacterial infections; Hepatic encephalopathy; Skin and soft tissue infections
  • No development reported Helicobacter infections; Irritable bowel syndrome

Most Recent Events

  • 03 Apr 2025 Phase-I/II clinical trials in Bacterial infections (Combination therapy) in China (Intra-articular) (NCT06889701)
  • 25 Mar 2025 TenNor Therapeutics plans a phase I/II trial for Bacterial infections in China (Intra-articular) in March 2025 (NCT06889701)
  • 28 Dec 2024 No recent reports of development identified for clinical-Phase-Unknown development in Irritable-bowel-syndrome in China (PO, Capsule)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top